YiChen Biotech

Yichen Biotech is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of mRNA-based therapeutics and vaccines. The company leverages a proprietary mRNA technology platform and lipid nanoparticle (LNP) delivery systems to target infectious diseases and oncology. Its lead programs include mRNA vaccines for COVID-19, respiratory syncytial virus (RSV), and herpes zoster. Yichen Biotech aims to address significant unmet medical needs through rapid vaccine development and innovative immunotherapy solutions. The company has attracted significant investment from prominent venture capital firms, including GL Ventures and Qiming Venture Partners, to accelerate its clinical pipeline. With a focus on high-efficiency delivery and optimized mRNA sequences, Yichen is positioned as a key player in the emerging Chinese mRNA landscape.